News & Events

12 May 2025

Exciting Liver Health Helix Event on Wednesday, 4 June 2025

The upcoming Liver Health Helix Event on Wednesday, 04 June 2025, from 11:00 - 12:30 CEST (10:00 - 11:30 BST) about the challenges of drug development for clinical trials is an exciting open innovation event designed to accelerate the development of new treatments for liver diseases, particularly severe alcoholic hepatitis (sAH), advanced cirrhosis, and acute-on-chronic liver failure (ACLF). Taking place in support of the A-TANGO project and related research initiatives, this event brings together leading hepatologists, cirrhosis researchers, industry professionals, and investors to explore the latest breakthroughs, share expertise, and spark impactful collaborations. Now is the time to secure your spot in this vibrant and forward-thinking community. Register here!

13 May 2025

Meet the Experts: Speaker Lineup at the Helix Event

Our Liver Health Helix Event on 04 June 2025 features an exceptional lineup of speakers from the fields of hepatology, clinical research, drug development, and bioinformatics. Troels Jordansen, CEO of Yaqrit, Cornelius Engelmann, clinical trial supervisor at the Charité, Burcu Kiper, Impact Acceleration Manager at Crowdhelix, and guest speaker Salvador Augustin from Boehringer Ingelheim will keep you on your toes. They will share valuable insights into the latest therapeutic strategies, innovative approaches, and ways to overcome the challenges of clinical trials. Attendees will benefit from firsthand knowledge, real-world case studies, and opportunities to engage directly with some of the brightest minds in liver disease research and drug development.

14 May 2025

The Agenda: Challenges of Drug Development for Clincal Trials

Feeling optimistic about incorporating both drug development and drug manufacturing into your 5-year-long EU-funded research project? Well, according to Troels Jordanson, CEO of Yaqrit, "if it can go wrong, it ...". The upcoming Helix Event on 04 June 2025 is packed with fun and interactive sessions designed to foster knowledge exchange and drive real progress in liver disease treatment. Topics will range from drug development bottlenecks and clinical trial design to cutting-edge applications in data science and bioinformatics. Dedicated networking opportunities and panel discussions will allow participants to explore shared challenges and uncover new paths toward collaboration. The program is designed to inspire innovation and equip attendees with actionable insights that can lead to meaningful change. Don't forget to register for this exciting online session!

OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more

OBJECTIVES

  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more

SCIENTIFIC COORDINATOR

Prof. Dr. Rajiv Jalan (EF CLIF)
Av. Diagonal 477, 11th floor
08036 Barcelona
Spain

CLINICAL STUDY SUPERVISOR

Dr. med. Cornelius Engelmann (MD, PhD) (Charité)
Augustenburger Platz 1
13353 Berlin
Germany

PROJECT
MANAGEMENT

concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck
Germany